Benzatropine
- Generic Name
- Benzatropine
- Brand Names
- Cogentin
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25NO
- CAS Number
- 86-13-5
- Unique Ingredient Identifier
- 1NHL2J4X8K
- Background
Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.
- Indication
用于治疗帕金森病。也用于药物引起的锥体外系疾患，口服1小时起效，肌肉或静脉注射数分钟内起效，作用持续24小时。具有抗胆碱及抗组胺作用，并有轻度局部麻醉作用。
- Associated Conditions
- Parkinsonism
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT01795716
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai, China
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
- Conditions
- Malignancies
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Pathway Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01407380
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
Efficacy of Antidepressants in Chronic Back Pain
- Conditions
- Back Pain
- Interventions
- Behavioral: cognitive behavioral therapy
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 142
- Registration Number
- NCT00964886
- Locations
- 🇺🇸
VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 21
- Registration Number
- NCT00802100
- Locations
- 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸SHANTI Clinical Trials, Colton, California, United States
Anticholinergic Burden in Schizophrenia
- Conditions
- Schizophreniform DisorderSchizophreniaSchizoaffective DisorderDelusional DisorderPsychotic Disorders
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2015-08-24
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 2
- Registration Number
- NCT00715377
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
- Conditions
- Active, Moderate to Severe Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 35
- Registration Number
- NCT00642629
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
- Conditions
- Agitation
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 72
- Registration Number
- NCT00457366
- Locations
- 🇺🇸
Los Angeles County Hospital, Los Angeles, California, United States
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 12
- Registration Number
- NCT00234741
- Locations
- 🇺🇸
Nih/Niaid, Bethesda, Maryland, United States
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Synta Pharmaceuticals Corp.
- Target Recruit Count
- 282
- Registration Number
- NCT00138840
- Locations
- 🇺🇸
Maryland Digestive Disease Research, Laurel, Maryland, United States
🇺🇸Capital Gastroenterology Consultants, P.A., Silver Spring, Maryland, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)
- Conditions
- Temporomandibular Joint Disorders
- Interventions
- Behavioral: CBTBehavioral: Disease MGT
- First Posted Date
- 2003-08-08
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 140
- Registration Number
- NCT00066937
- Locations
- 🇺🇸
University of Maryland, Dental School, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.